Itacitinib for adults with diffuse systemic sclerosis
Treatments studied
Part of Skin clinical trials.
This Phase 2 study tests itacitinib, a targeted medicine, to see if it can safely improve diffuse systemic sclerosis (a hardening/tightening of the skin and organ involvement). You may be eligible if you have active disease or it has been present less than 3 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have diffuse systemic sclerosis (not limited) confirmed by specific medical criteria
- Your disease is active, or it started less than 36 months ago
- Your skin thickening score is between 10 and 35 at screening
- If you can become pregnant: you have a negative pregnancy test and use reliable birth control during the study
- Your blood tests are high enough: white blood cells above 4,000 and platelets above 100,000, with liver enzymes not more than 3x normal
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This study tests an experimental cell therapy that targets your own immune cells to treat systemic sclerosis (scleroderma) with lung involvement. It aims to see if this treatment works better than standard care in reducing disease activity.
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
This trial tests a new CAR-T cell therapy called relmacabtagene autoleucel for people with diffuse systemic sclerosis (scleroderma) that is not responding to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.